Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter Open-label Study to Evaluate the Safety and Efficacy of Standardized Initial Therapy Using Either Mesalamine or Corticosteroids Then Mesalamine for the Treatment of Children and Adolescents Newly Diagnosed With Ulcerative Colitis.

Next Previous
Trial Profile

Multicenter Open-label Study to Evaluate the Safety and Efficacy of Standardized Initial Therapy Using Either Mesalamine or Corticosteroids Then Mesalamine for the Treatment of Children and Adolescents Newly Diagnosed With Ulcerative Colitis.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mesalazine (Primary) ; Anti-TNF alpha domain antibody; Azathioprine; Ciclosporin; Immunomodulators; Prednisone; Prednisone; Tacrolimus
  • Indications Ulcerative colitis
  • Focus Biomarker; Therapeutic Use
  • Acronyms PROTECT

Most Recent Events

  • 23 May 2021 Results assessing the prognostic ability of our gene expression array for predicting outcomes in a large inception cohort study, PROTECT, of children with ulcerative-colitis treated with standardized therapy based on initial clinical severity, presented at the Digestive Disease Week 2021.
  • 02 Aug 2019 Primary endpoint (Corticosteroid free remission (SFR)) has been met according to Results published in the Alimentary Pharmacology and Therapeutics.
  • 02 Aug 2019 Results published in the Alimentary Pharmacology and Therapeutics.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top